The interdependence of targets for continuous glucose monitoring outcomes in type 1 diabetes with automated insulin delivery

被引:2
|
作者
Castaneda, Javier [1 ]
de Galan, Bastiaan E. [2 ,3 ,4 ]
van Kuijk, Sander M. J. [5 ]
Arrieta, Arcelia [1 ]
van den Heuvel, Tim [1 ]
Cohen, Ohad [1 ]
机构
[1] Medtron Int Trading Sarl, Route Molliau 31, CH-1131 Tolochenaz, Switzerland
[2] Maastricht Univ Med Ctr, Dept Internal Med, Maastricht, Netherlands
[3] Maastricht Univ, CARIM Sch Cardiovasc Dis, Maastricht, Netherlands
[4] Radboud Univ Nijmegen Med Ctr, Dept Internal Med, Nijmegen, Netherlands
[5] Maastricht Univ Med Ctr, Dept Clin Epidemiol & Med Technol Assessment, Maastricht, Netherlands
来源
DIABETES OBESITY & METABOLISM | 2024年 / 26卷 / 12期
关键词
glycaemic control; hypoglycaemia; mean glucose; real-world evidence; time in tight glucose range; REAL-WORLD USERS; SYSTEM; RANGE; TIME;
D O I
10.1111/dom.15955
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: The aim was to determine the interdependence of targets for glucose management indicator (GMI), time within the ranges of 70-180 mg/dL (TIR) and 70-140 mg/ dL (time in tight glucose range [TITR]), time above 180 mg/dL (TA180) and 250 mg/ dL (TA250) and time below 70 mg/dL (TB70) and 54 mg/dL (TB54) and its implications for setting targets in automated insulin delivery (AID). Materials and Methods: Real-world data from individuals with type 1 diabetes using the 780G system were used to calculate the receiver operating characteristic curves and establish interdependent targets for time in ranges based on several GMI benchmarks. Correlation, regression and principal component analysis were used to determine their association and dimensionality. Results: In individuals aged >15 years (n n = 41 692), a GMI <6.5% required targets of >81%, >58%, <15% and <1.9% for TIR, TITR, TA180 and TA250, respectively, with high sensitivity, specificity and accuracy (>90%), whereas these values were poor for time in hypoglycaemia and GMI, which had a modest correlation (-0.21 to-0.43). Two dimensions emerged: (1) GMI, TIR, TITR, TA180 and TA250, and (2) TB70 and TB54, explaining 95% of total variability. GMI (or TIR) and TB70 explained >81% of the variability in the remaining continuous glucose monitoring (CGM) metrics, providing accurate predictions. Individuals aged <= 15 years (n n = 14 459) showed similar results. Conclusion: We developed a methodology to establish interdependent CGM targets for therapies with CGM data outputs. In AID with the 780G system, a GMI <7% requires time in ranges close to consensus targets. Targets for GMI, TIR, TITR, TA180 and TA250 could be reduced to targets for GMI or TIR, whereas targets for time in hypoglycaemia are not inherently tied to GMI/TIR targets.
引用
收藏
页码:5836 / 5844
页数:9
相关论文
共 50 条
  • [1] Effect of Continuous Glucose Monitoring and Automated Insulin Delivery System on Glycemic Control in Children with Type 1 Diabetes
    Tantivit, Nessa
    Kaulfers, Anne-Marie
    Mulekar, Madhuri
    HORMONE RESEARCH IN PAEDIATRICS, 2023, 96 (SUPPL 3): : 57 - 59
  • [2] Diabetes technologies in people with type 1 diabetes mellitus and disordered eating: A systematic review on continuous subcutaneous insulin infusion, continuous glucose monitoring and automated insulin delivery
    Priesterroth, Lilli
    Grammes, Jennifer
    Clauter, Mona
    Kubiak, Thomas
    DIABETIC MEDICINE, 2021, 38 (07)
  • [3] Continuous Glucose Monitor, Insulin Pump, and Automated Insulin Delivery Therapies for Type 1 Diabetes: An Update on Potential for Cardiovascular Benefits
    Pauley, Meghan E.
    Tommerdahl, Kalie L.
    Snell-Bergeon, Janet K.
    Forlenza, Gregory P.
    CURRENT CARDIOLOGY REPORTS, 2022, 24 (12) : 2043 - 2056
  • [4] Continuous Glucose Monitor, Insulin Pump, and Automated Insulin Delivery Therapies for Type 1 Diabetes: An Update on Potential for Cardiovascular Benefits
    Meghan E. Pauley
    Kalie L. Tommerdahl
    Janet K. Snell-Bergeon
    Gregory P. Forlenza
    Current Cardiology Reports, 2022, 24 : 2043 - 2056
  • [5] Continuous Glucose Monitoring and Insulin Informed Advisory System with Automated Titration and Dosing of Insulin Reduces Glucose Variability in Type 1 Diabetes Mellitus
    Breton, Marc D.
    Patek, Stephen D.
    Lv, Dayu
    Schertz, Elaine
    Robic, Jessica
    Pinnata, Jennifer
    Kollar, Laura
    Barnett, Charlotte
    Wakeman, Christian
    Oliveri, Mary
    Fabris, Chiara
    Chernavvsky, Daniel
    Kovatchev, Boris P.
    Anderson, Stacey M.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 (08) : 531 - 540
  • [6] Continuous Glucose Monitoring in Patients With Type 1 Diabetes Using Insulin Injections
    Foster, Nicole C.
    Miller, Kellee M.
    Tamborlane, William V.
    Bergenstal, Richard M.
    Beck, Roy W.
    DIABETES CARE, 2016, 39 (06) : E81 - E82
  • [7] Continuous Glucose Monitoring in Patients With Type 1 Diabetes Taking Insulin Injections
    Davidson, Mayer B.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (04): : 363 - 364
  • [8] Professional Continuous Glucose Monitoring Improves Diabetes Outcomes in Children with Type 1 Diabetes
    Willi, Steven M.
    Raquib, Aaishah
    Tobolski, Jared
    Isaacs, Charles J.
    Minnock, Pantea
    DIABETES, 2014, 63 : A224 - A224
  • [9] Continuous glucose monitoring in type 1 diabetes
    Weinzimer S.A.
    Tamborlane W.V.
    Chase P.
    Garg S.K.
    Current Diabetes Reports, 2004, 4 (2) : 95 - 100
  • [10] Continuous glucose monitoring in type 1 diabetes
    Nelly Mauras
    Larry Fox
    Kimberly Englert
    Roy W. Beck
    Endocrine, 2013, 43 : 41 - 50